Exploring the landscape of diazabicyclooctane (DBO) inhibition: Avibactam inactivation of PER-2 β-Lactamase

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 6, 2017, Pages

  Ruggiero, Melina ^a   Papp Wallace, Krisztina M ^b,c   Taracila, Magdalena A ^b,c   Mojica, Maria F ^b,c   Bethel, Christopher R ^b   Rudin, Susan D ^b,c   Zeiser, Elise T ^b   Gutkind, Gabriel ^a,d   Bonomo, Robert A ^b,c   Power, Pablo ^a,d  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

Avibactam; Beta lactamases; Beta lactams

Indexed keywords

AVIBACTAM; CARBONYL DERIVATIVE; CARBOXYLIC ACID; CEFTAROLINE; EXTENDED SPECTRUM BETA LACTAMASE; PER 2 BETA LACTAMASE; SULFATE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; AZABICYCLO DERIVATIVE; BETA LACTAMASE; BETA-LACTAMASE PER-2, ENTEROBACTERIACEAE;

ACYLATION; ARTICLE; BINDING SITE; CARBAMOYLATION; CONTROLLED STUDY; DRUG SCREENING; ENTEROBACTERIACEAE; ENZYME INACTIVATION; EQUILIBRIUM CONSTANT; INHIBITION CONSTANT; INHIBITION KINETICS; MASS SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR MODEL; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RATE CONSTANT; STEADY STATE; METABOLISM; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAMASES; MICROBIAL SENSITIVITY TESTS;

EID: 85019741310     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02476-16     Document Type: Article

References (32)

1. Quinteros M, Radice M, Gardella N, Rodriguez MM, Costa N, Korbenfeld D, Couto E, Gutkind G, The Microbiology Study Group. 2003. Extendedspectrum lactamases in Enterobacteriaceae in Buenos Aires, Argentina, public hospitals. Antimicrob Agents Chemother 47:2864 -2867. https://doi.org/10.1128/AAC.47.9.2864-2867.2003.
2. Gutkind GO, Di Conza, J, Power P, Radice M. 2013. Lactamase-mediated resistance: A biochemical, epidemiological and genetic overview. Curr Pharm Des 19:164 -208. https://doi.org/10.2174/138161213804070320.
3. Power P, Di Conza J, Rodriguez MM, Ghiglione B, Ayala JA, Casellas JM, Radice M, Gutkind G. 2007. Biochemical characterization of PER-2 and genetic environment of blaPER-2. Antimicrob Agents Chemother 51: 2359-2365. https://doi.org/10.1128/AAC.01395-06.
4. Bouthors AT, Delettre J, Mugnier P, Jarlier V, Sougakoff W. 1999. Sitedirected mutagenesis of residues 164, 170, 171, 179, 220, 237 and 242 in PER-1 lactamase hydrolysing expanded-spectrum cephalosporins. Protein Eng 12:313-318. https://doi.org/10.1093/protein/12.4.313.
5. Ruggiero M, Kerff F, Herman R, Sapunaric F, Galleni M, Gutkind G, Charlier P, Sauvage E, Power P. 2014. Crystal structure of the extendedspectrum lactamase PER-2 and insights into the role of specific residues in the interaction with lactams and lactamase inhibitors. Antimicrob Agents Chemother 58:5994-6002. https://doi.org/10.1128/AAC.00089-14.
6. Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Kern G, Walkup GK, Fisher SL. 2012. Avibactam is a covalent, reversible, non lactam lactamase inhibitor. Proc Natl Acad Sci U S A 109:11663-11668. https://doi.org/10.1073/pnas.1205073109.
7. Endimiani A, Choudhary Y, Bonomo RA. 2009. In vitro activity of NXL104 in combination with -lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob Agents Chemother 53:3599 -3601. https://doi.org/10.1128/AAC.00641-09.
8. Lagace-Wiens PR, Tailor F, Simner P, DeCorby M, Karlowsky JA, Walkty A, Hoban DJ, Zhanel GG. 2011. Activity of NXL104 in combination with lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum -lactamases and class C lactamases. Antimicrob Agents Chemother 55:2434 -2437. https://doi.org/10.1128/AAC.01722-10.
9. Livermore DM, Mushtaq S, Warner M, Miossec C, Woodford N. 2008. NXL104 combinations versus Enterobacteriaceae with CTX-M extendedspectrum lactamases and carbapenemases. J Antimicrob Chemother 62:1053-1056. https://doi.org/10.1093/jac/dkn320.
10. Mushtaq S, Warner M, Williams G, Critchley I, Livermore DM. 2010. Activity of chequerboard combinations of ceftaroline and NXL104 versus lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 65: 1428-1432. https://doi.org/10.1093/jac/dkq161.
11. Stachyra T, Levasseur P, Pechereau MC, Girard AM, Claudon M, Miossec C, Black MT. 2009. In vitro activity of the lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J Antimicrob Chemother 64:326 -329. https://doi.org/10.1093/jac/dkp197.
12. Papp-Wallace KM, Bajaksouzian S, Abdelhamed AM, Foster AN, Winkler ML, Gatta JA, Nichols WW, Testa R, Bonomo RA, Jacobs MR. 2015. Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single lactamases. Diagn Microbiol Infect Dis 82:65- 69. https://doi.org/10.1016/j.diagmicrobio.2015.02.003.
13. Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Durand-Reville TF, Lahiri S, Thresher J, Livchak S, Gao N, Palmer T, Walkup GK, Fisher SL. 2013. Kinetics of avibactam inhibition against class A, C, and D lactamases. J Biol Chem 288:27960-27971. https://doi.org/10.1074/jbc.M113.485979.
14. Krishnan NP, Nguyen NQ, Papp-Wallace KM, Bonomo RA, van den Akker, F. 2015. Inhibition of Klebsiella lactamases (SHV-1 and KPC-2) by avibactam: A structural study. PLoS One 10:e0136813. https://doi.org/10.1371/journal.pone.0136813.
15. Lahiri SD, Mangani S, Jahic H, Benvenuti M, Durand-Reville TF, De Luca F, Ehmann DE, Rossolini GM, Alm RA, Docquier JD. 2015. Molecular basis of selective inhibition and slow reversibility of avibactam against class D carbapenemases: A structure-guided study of OXA-24 and OXA-48. ACS Chem Biol 10:591- 600. https://doi.org/10.1021/cb500703p.
16. Winkler ML, Papp-Wallace KM, Bonomo RA. 2015. Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV lactamases with single amino acid substitutions in the loop. J Antimicrob Chemother 70:2279-2286. https://doi.org/10.1093/jac/dkv094.
17. Drawz SM, Bonomo RA. 2010. Three decades of lactamase inhibitors. Clin Microbiol Rev 23:160 -201. https://doi.org/10.1128/CMR.00037-09.
18. Lahiri SD, Johnstone MR, Ross PL, McLaughlin RE, Olivier NB, Alm RA. 2014. Avibactam and class C -lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance. Antimicrob Agents Chemother 58:5704 -5713. https://doi.org/10.1128/AAC.03057-14.
19. Lahiri SD, Mangani S, Durand-Reville T, Benvenuti M, De Luca, F, Sanyal G, Docquier JD. 2013. Structural insight into potent broad-spectrum inhibition with reversible recyclization mechanism: Avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC lactamases. Antimicrob Agents Chemother 57:2496 -2505. https://doi.org/10.1128/AAC.02247-12.
20. Lahiri SD, Walkup GK, Whiteaker JD, Palmer T, McCormack K, Tanudra MA, Nash TJ, Thresher J, Johnstone MR, Hajec L, Livchak S, McLaughlin RE, Alm RA. 2015. Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC. J Antimicrob Chemother 70: 1650-1658. https://doi.org/10.1093/jac/dkv004.
21. Lahiri SD, Bradford PA, Nichols WW, Alm RA. 2016. Structural and sequence analysis of class A lactamases with respect to avibactam inhibition: impact of loop variations. J Antimicrob Chemother 71: 2848-2855. https://doi.org/10.1093/jac/dkw248.
22. Winkler ML, Papp-Wallace KM, Taracila MA, Bonomo RA. 2015. Avibactam and inhibitor-resistant SHV lactamases. Antimicrob Agents Chemother 59:3700 -3709. https://doi.org/10.1128/AAC.04405-14.
23. Papp-Wallace KM, Winkler ML, Gatta JA, Taracila MA, Chilakala S, Xu Y, Johnson JK, Bonomo RA. 2014. Reclaiming the efficacy of lactam lactamase inhibitor combinations: Avibactam restores the susceptibility of CMY-2-producing Escherichia coli to ceftazidime. Antimicrob Agents Chemother 58:4290-4297. https://doi.org/10.1128/AAC.02625-14.
24. Karlowsky JA, Biedenbach DJ, Bouchillon SK, Iaconis JP, Reiszner E, Sahm DF. 2016. In vitro activity of ceftaroline against bacterial pathogens isolated from skin and soft tissue infections in Europe, Russia and Turkey in 2012: Results from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance programme. J Antimicrob Chemother 71:162-169. https://doi.org/10.1093/jac/dkv311.
25. Clinical and Laboratory Standards Institute. 2016. Performance standards for antimicrobial susceptibility testing; twenty-sixth informational supplement. CLSI document M100-S26. Clinical and Laboratory Standards Institute, Wayne, PA.
26. Segel IH. 1975. Enzyme kinetics, behavior and analysis of rapid equilibrium and steady-state enzyme systems. John Wiley & Sons, Inc., New York, NY.
27. Papp-Wallace KM, Becka SA, Taracila MA, Winkler ML, Gatta JA, Rholl DA, Schweizer HP, Bonomo RA. 2016. Exposing a lactamase "twist": The mechanistic basis for the high level of ceftazidime resistance in the C69F variant of the Burkholderia pseudomallei PenI lactamase. Antimicrob Agents Chemother 60:777-788. https://doi.org/10.1128/AAC.02073-15.
28. Wu G, Robertson DH, Brooks CL III, Vieth M. 2003. Detailed analysis of grid-based molecular docking: A case study of CDOCKER-A CHARMmbased MD docking algorithm. J Comput Chem 24:1549 -1562. https://doi.org/10.1002/jcc.10306.
29. Papp-Wallace KM, Winkler ML, Taracila MA, Bonomo RA. 2015. Variants of lactamase KPC-2 that are resistant to inhibition by avibactam. Antimicrob Agents Chemother 59:3710 -3717. https://doi.org/10.1128/AAC.04406-14.
30. Livermore DM, Warner M, Jamrozy D, Mushtaq S, Nichols WW, Mustafa N, Woodford N. 2015. In vitro selection of ceftazidime-Avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase. Antimicrob Agents Chemother 59:5324 -5330. https://doi.org/10.1128/AAC.00678-15.
31. Haidar G, Clancy CJ, Shields RK, Hao B, Cheng S, Nguyen MH. 2017. Mutations in blaKPC-3 that confer ceftazidime-Avibactam resistance encode novel KPC-3 variants that function as extended-spectrum lactamases. Antimicrob Agents Chemother 61:02534-16. https://doi.org/10.1128/AAC.02534-16.
32. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-7th ed. CLSI document M7-A7. Clinical and Laboratory Standards Institute. Wayne, Pa.